For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic use.
Menu
Reconstitution calculator

Tissue biology research

ARA-290 Dosage, Protocol & Research Guide

Evidence grade Human clinical trialBy Sam, MBALast reviewed October 2026

  • MW 1,257.3 g/mol
  • CAS 1208243-50-8
Dosage, protocol, reconstitution and storage reference for ARA-290, with a reconstitution calculator, vial sizes and cited research.

Dose overview

Every range below is taken from the cited source and carries its evidence grade.

Human data and community reports

Human data and community reports
SourcePopulationDoseFrequencyRouteDurationEvidence
Mol Med 2013 (doi 10.2119/molmed.2013.00122; NTR3575)[2]human38 patients with sarcoidosis and small nerve fiber loss (21 ARA 290, 17 placebo)4 mg[2]subcutaneous, daily dose in the active armdaily for 28 dayssubcutaneous— Human clinical trialStudy details from the source: Mol Med 2013 (doi 10.2119/molmed.2013.00122; NTR3575): 38 sarcoidosis patients with small nerve fiber loss, 21 on ARA 290 4 mg subcutaneously daily for 28 days vs placebo; 4 mg chosen from a crossover pharmacokinetic study (2 mg IV, 2 mg SC, 4 mg SC, 6 mg)

Evidence grades: A approved label, B human trial, C observational, D animal study, E community-reported.

Reconstitution calculator

Sizes in the Pepcore catalogue10 mg
Concentration
5 mg/mL
Volume to draw
0.05 mL
Units on a U-100 syringe
5 units
Draws per vial
40

0102030405060708090100

Properties

CAS
1208243-50-8
Molecular weight
1,257.3 g/mol
Formula
Not yet recorded
Sequence
Not yet recorded
Aliases
Cibinetide, ARA 290
Vial sizes (mg)
10

Storage notes

Lyophilized
Not yet recorded from a cited source
Reconstituted stability (days)
Not yet recorded from a cited source

Side effects, contraindications and regulatory status

Reported side effects

  • Trial in sarcoidosis small-fiber neuropathy (38 patients; 21 on ARA 290 4 mg subcutaneously daily for 28 days): no serious adverse events during dosing or 12 weeks of follow-up; no pain or local irritation at the injection site.[2] Human trial
  • Same trial: one ARA 290 patient had a moderate adverse event of 14 kg weight loss that, per the paper, began before study entry and persisted after dosing stopped; no anti-ARA 290 antibodies were detected in the post-dose samples tested.[2] Human trial
  • Registry results, daily subcutaneous dosing for 28 days: serious adverse events in 2 of 16 (1 mg), 0 of 16 (4 mg), 1 of 14 (8 mg; suicidal ideation) and 0 of 16 (placebo) participants; headache, nausea and diarrhea were among other events listed.[1] Human trial

Cautions from reviews and trials

  • Trial exclusion (registry NCT02039687): pregnancy or breast-feeding; use of erythropoiesis-stimulating agents within two months before screening or during the trial; serious malignancy within the last 5 years (other than removed skin carcinoma).[1] Human trial

Regulatory status

Investigational: phase 2 registry record NCT02039687 (completed 2015-02); the record lists no approval. Not on the FDA bulk-substance safety-risk page (2026-04-22). Checked 2026-10-20.[1] Source

Report any adverse reaction to a qualified healthcare professional.

What the research says

Summaries of the cited studies, each with its evidence grade.

  • Mol Med 2013 (doi 10.2119/molmed.2013.00122; NTR3575)[2]

    Human trial human

    Mol Med 2013 (doi 10.2119/molmed.2013.00122; NTR3575): 38 sarcoidosis patients with small nerve fiber loss, 21 on ARA 290 4 mg subcutaneously daily for 28 days vs placebo; 4 mg chosen from a crossover pharmacokinetic study (2 mg IV, 2 mg SC, 4 mg SC, 6 mg)

    Human clinical trial

  • ClinicalTrials.gov NCT02039687 (phase 2, 64 enrolled)[1]

    Human trial human

    ClinicalTrials.gov NCT02039687 (phase 2, 64 enrolled): daily subcutaneous ARA 290 at 1, 4 or 8 mg or placebo for 28 days, 12-week follow-up; self-injected at home after the first dose at the site

    Human clinical trial

Compare vial sizes

Compare vial sizes
SizePriceDoses available from the vial CalculatedCost per dose Calculated
10 mg$64.992$32.50

Cost per dose uses the listed partner price and the reference dose cited on this page. Prices change; check the product page.

Calculated from a default of 2 mL water (adjustable).

Peptide Protocol Check may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.

Frequently asked questions

What dose figures are published for ARA-290?

Cited figures on this page: 4 mg daily for 28 days, subcutaneous, daily dose in the active arm [2] (Human clinical trial, evidence grade B). These are summaries of published sources, not medical advice. Each figure links to its source in the references.

What is the regulatory status of ARA-290?

Investigational: phase 2 registry record NCT02039687 (completed 2015-02); the record lists no approval. Not on the FDA bulk-substance safety-risk page (2026-04-22). Checked 2026-10-20.

Compound facts

Recorded molecular weight: 1,257.3 g/mol.
Recorded CAS number: 1208243-50-8
Not yet recorded from a cited source.

Sources

https://pubchem.ncbi.nlm.nih.gov/compound/91810664
PubMed IDs
Not yet recorded

References

Numbered sources used on this page. Markers in the text link here.

  1. ClinicalTrials.gov NCT02039687 (phase 2, 64 enrolled) clinicaltrials.gov Human trial
  2. Mol Med 2013 (doi 10.2119/molmed.2013.00122; NTR3575) pmc.ncbi.nlm.nih.gov Human trial

Vial sizes and protocols

Calculated from a default of 2 mL water (adjustable).

Available from Pepcore

Supplied as research material for laboratory use only.

  • ARA-290 Research Material - 10mg 10 mg$64.99
    Shop at PepcoreCoupon code LAUNCH20

Peptide Protocol Check may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.